Turning science into solutions
Posted by
09-Apr-2014
When the history of drug discovery is written, the chapter on the 21st century will have a large section dedicated to open innovation.
There has been a growing acceptance recently that while medical needs remain unmet, no single university, research institute or company alone can deliver what patients need.
Yes, the knowledge and tools we have to tackle major health challenges have advanced, but so too have their complexity. The only way forward is through partnership.
Of course, finding the right research partners is essential. Partners need to share the same spirit and common goals, yet bring unique perspectives and skills that make the collaboration greater than the sum of its parts.
At UCB, we have expanded our network of partners in a thoughtful and strategic way that fits with our promise to be Inspired by Patients. Driven by Science.
We are collaborating with other companies and academia - such as Harvard and Oxford - and even with a Nobel Prize winner.
Our most recent partnership is with Weill Cornell Medical College, Cornell University’s medical school in New York City.
This major strategic alliance aims to convert scientific discovery into transformative health improvements in areas of high patient need.
UCB will fund research and our scientists will collaborate closely with scientists at Weill Cornell on three translational programmes over three years, in the areas of bone disorders, metabolic disease and rare genetic variant analysis.
These projects fit with a key strategy of UCB NewMedicines to focus on the discovery of medicines targeting pathways with a high level validation in humans, including genetic validation.
Combining Weill Cornell’s world-class academic research with our discovery team has the potential to transform the lives of people with severe diseases.
Partnerships accelerate progress. And that is what we are all about.
There has been a growing acceptance recently that while medical needs remain unmet, no single university, research institute or company alone can deliver what patients need.
Yes, the knowledge and tools we have to tackle major health challenges have advanced, but so too have their complexity. The only way forward is through partnership.
Of course, finding the right research partners is essential. Partners need to share the same spirit and common goals, yet bring unique perspectives and skills that make the collaboration greater than the sum of its parts.
At UCB, we have expanded our network of partners in a thoughtful and strategic way that fits with our promise to be Inspired by Patients. Driven by Science.
We are collaborating with other companies and academia - such as Harvard and Oxford - and even with a Nobel Prize winner.
Our most recent partnership is with Weill Cornell Medical College, Cornell University’s medical school in New York City.
This major strategic alliance aims to convert scientific discovery into transformative health improvements in areas of high patient need.
UCB will fund research and our scientists will collaborate closely with scientists at Weill Cornell on three translational programmes over three years, in the areas of bone disorders, metabolic disease and rare genetic variant analysis.
These projects fit with a key strategy of UCB NewMedicines to focus on the discovery of medicines targeting pathways with a high level validation in humans, including genetic validation.
Combining Weill Cornell’s world-class academic research with our discovery team has the potential to transform the lives of people with severe diseases.
Partnerships accelerate progress. And that is what we are all about.
Leave a Comment